Trial Profile
A Pilot Study Investigating the Effects of Lipid-therapy Intensification With Alirocumab on Endothelial Function, Carotid Arteries, Lipoprotein Particle Subfractions, Inflammation and Post-prandial Lipemia in Clinical Routine
Status:
Discontinued
Phase of Trial:
Phase IV
Latest Information Update: 04 Nov 2021
Price :
$35
*
At a glance
- Drugs Alirocumab (Primary)
- Indications Hypercholesterolaemia
- Focus Pharmacodynamics
- Acronyms ALIROCKS
- 20 Apr 2020 Status changed from active, no longer recruiting to discontinued.
- 07 Feb 2020 Planned End Date changed from 1 Jan 2020 to 1 Aug 2020.
- 07 Feb 2020 Planned primary completion date changed from 1 Dec 2019 to 1 Jul 2020.